607 related articles for article (PubMed ID: 8643684)
1. Intergenic splicing of MDS1 and EVI1 occurs in normal tissues as well as in myeloid leukemia and produces a new member of the PR domain family.
Fears S; Mathieu C; Zeleznik-Le N; Huang S; Rowley JD; Nucifora G
Proc Natl Acad Sci U S A; 1996 Feb; 93(4):1642-7. PubMed ID: 8643684
[TBL] [Abstract][Full Text] [Related]
2. Rearrangement of the AML1/CBFA2 gene in myeloid leukemia with the 3;21 translocation: expression of co-existing multiple chimeric genes with similar functions as transcriptional repressors, but with opposite tumorigenic properties.
Zent C; Kim N; Hiebert S; Zhang DE; Tenen DG; Rowley JD; Nucifora G
Curr Top Microbiol Immunol; 1996; 211():243-52. PubMed ID: 8585955
[TBL] [Abstract][Full Text] [Related]
3. Consistent intergenic splicing and production of multiple transcripts between AML1 at 21q22 and unrelated genes at 3q26 in (3;21)(q26;q22) translocations.
Nucifora G; Begy CR; Kobayashi H; Roulston D; Claxton D; Pedersen-Bjergaard J; Parganas E; Ihle JN; Rowley JD
Proc Natl Acad Sci U S A; 1994 Apr; 91(9):4004-8. PubMed ID: 8171026
[TBL] [Abstract][Full Text] [Related]
4. MDS1/EVI1 enhances TGF-beta1 signaling and strengthens its growth-inhibitory effect but the leukemia-associated fusion protein AML1/MDS1/EVI1, product of the t(3;21), abrogates growth-inhibition in response to TGF-beta1.
Sood R; Talwar-Trikha A; Chakrabarti SR; Nucifora G
Leukemia; 1999 Mar; 13(3):348-57. PubMed ID: 10086725
[TBL] [Abstract][Full Text] [Related]
5. Rearrangements of the AML1/CBFA2 gene in myeloid leukemia with the 3;21 translocation: in vitro and in vivo studies.
Zent C; Rowley JD; Nucifora G
Leukemia; 1997 Apr; 11 Suppl 3():273-8. PubMed ID: 9209363
[TBL] [Abstract][Full Text] [Related]
6. The EVI1 gene in myeloid leukemia.
Nucifora G
Leukemia; 1997 Dec; 11(12):2022-31. PubMed ID: 9447815
[TBL] [Abstract][Full Text] [Related]
7. The leukemia-associated gene MDS1/EVI1 is a new type of GATA-binding transactivator.
Soderholm J; Kobayashi H; Mathieu C; Rowley JD; Nucifora G
Leukemia; 1997 Mar; 11(3):352-8. PubMed ID: 9067573
[TBL] [Abstract][Full Text] [Related]
8. Activation of a novel gene in 3q21 and identification of intergenic fusion transcripts with ecotropic viral insertion site I in leukemia.
Pekarsky Y; Rynditch A; Wieser R; Fonatsch C; Gardiner K
Cancer Res; 1997 Sep; 57(18):3914-9. PubMed ID: 9307271
[TBL] [Abstract][Full Text] [Related]
9. [Study of genes involved in chronic myeloid leukemia with t (3; 21) (q26; q22) in blastic crisis].
Liu XP; Zhang MR; Dai Y; Zhang L; Li R; Hao YS; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2006 May; 27(5):310-3. PubMed ID: 16875579
[TBL] [Abstract][Full Text] [Related]
10. The chimeric genes AML1/MDS1 and AML1/EAP inhibit AML1B activation at the CSF1R promoter, but only AML1/MDS1 has tumor-promoter properties.
Zent CS; Mathieu C; Claxton DF; Zhang DE; Tenen DG; Rowley JD; Nucifora G
Proc Natl Acad Sci U S A; 1996 Feb; 93(3):1044-8. PubMed ID: 8577711
[TBL] [Abstract][Full Text] [Related]
11. A novel gene, MEL1, mapped to 1p36.3 is highly homologous to the MDS1/EVI1 gene and is transcriptionally activated in t(1;3)(p36;q21)-positive leukemia cells.
Mochizuki N; Shimizu S; Nagasawa T; Tanaka H; Taniwaki M; Yokota J; Morishita K
Blood; 2000 Nov; 96(9):3209-14. PubMed ID: 11050005
[TBL] [Abstract][Full Text] [Related]
12. The AML1 gene: a transcription factor involved in the pathogenesis of myeloid and lymphoid leukemias.
Lo Coco F; Pisegna S; Diverio D
Haematologica; 1997; 82(3):364-70. PubMed ID: 9234595
[TBL] [Abstract][Full Text] [Related]
13. AML1 and the 8;21 and 3;21 translocations in acute and chronic myeloid leukemia.
Nucifora G; Rowley JD
Blood; 1995 Jul; 86(1):1-14. PubMed ID: 7795214
[No Abstract] [Full Text] [Related]
14. Generation of the AML1-EVI-1 fusion gene in the t(3;21)(q26;q22) causes blastic crisis in chronic myelocytic leukemia.
Mitani K; Ogawa S; Tanaka T; Miyoshi H; Kurokawa M; Mano H; Yazaki Y; Ohki M; Hirai H
EMBO J; 1994 Feb; 13(3):504-10. PubMed ID: 8313895
[TBL] [Abstract][Full Text] [Related]
15. Identification of translocational breakpoints within the intron region before the last coding exon (exon 12) of the EVI1 gene in two cases of CML-BC with inv(3)(q21q26).
Suzukawa K; Taki T; Abe T; Asoh H; Kamada N; Yokota J; Morishita K
Genomics; 1997 Jun; 42(2):356-60. PubMed ID: 9192861
[TBL] [Abstract][Full Text] [Related]
16. Forced expression of the leukemia-associated gene EVI1 in ES cells: a model for myeloid leukemia with 3q26 rearrangements.
Sitailo S; Sood R; Barton K; Nucifora G
Leukemia; 1999 Nov; 13(11):1639-45. PubMed ID: 10557037
[TBL] [Abstract][Full Text] [Related]
17. t(3;21)(q26;q22) in myeloid leukemia: an aggressive syndrome of blast transformation associated with hydroxyurea or antimetabolite therapy.
Yin CC; Cortes J; Barkoh B; Hayes K; Kantarjian H; Jones D
Cancer; 2006 Apr; 106(8):1730-8. PubMed ID: 16532439
[TBL] [Abstract][Full Text] [Related]
18. High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients.
Barjesteh van Waalwijk van Doorn-Khosrovani S; Erpelinck C; van Putten WL; Valk PJ; van der Poel-van de Luytgaarde S; Hack R; Slater R; Smit EM; Beverloo HB; Verhoef G; Verdonck LF; Ossenkoppele GJ; Sonneveld P; de Greef GE; Löwenberg B; Delwel R
Blood; 2003 Feb; 101(3):837-45. PubMed ID: 12393383
[TBL] [Abstract][Full Text] [Related]
19. Quantitative comparison of the expression of EVI1 and its presumptive antagonist, MDS1/EVI1, in patients with myeloid leukemia.
Vinatzer U; Mannhalter C; Mitterbauer M; Gruener H; Greinix H; Schmidt HH; Fonatsch C; Wieser R
Genes Chromosomes Cancer; 2003 Jan; 36(1):80-9. PubMed ID: 12461752
[TBL] [Abstract][Full Text] [Related]
20. Both AML1 and EVI1 oncogenic components are required for the cooperation of AML1/MDS1/EVI1 with BCR/ABL in the induction of acute myelogenous leukemia in mice.
Cuenco GM; Ren R
Oncogene; 2004 Jan; 23(2):569-79. PubMed ID: 14724585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
